Lobbying Information
Subject Matters
- Constitutional Issues
- Health
- Industry
- Intellectual Property
- Internal Trade
- International Relations
- International Trade
- Justice and Law Enforcement
- Science and Technology
Subject Matter Details
Legislative Proposal, Bill or Resolution
- Canada's Food and Consumer Safety Action Plan proposes a series of initiatives to modernize and strengthen Canada's safety system for food, health and consumer products. Merck Frosst Canada seeking to ensure that Canada's safety system for medicines ensures safe and effective medicines for Canadians in a timely manner, consistent with other jurisdictions.
Policies or Program
- Canada's Access to Medicine Regime (CAMR) and its Regulations which provide a framework within which eligible developing countries can import less expensive generic versions of patented drugs and medical devices. Merck Frosst Canada seeking to ensure that those threatened by serious diseases have timely access to medicines for the diseases and that a research climate that will help to produce cures for other diseases is maintained.
- Health Canada's Blue Print for Renewal: Transforming Canada's Approach to Regulating Health Products and Food to renew the process for approving drugs. Merck Frosst Canada seeking to ensure that Canada's safety system for medicines ensures safe and effective medicines for Canadians in a timely manner, consistent with other jurisdictions.
- Patented Medicine Prices Review Board (PMPRB) Pricing Guidelines used by the PMPRB to ensure that prices of patented medicines sold in Canada are not excessive. Merck Frosst Canada seeking to ensure PMPRB Guidelines reflect their mandate of ensuring prices are non-excessive, while ensuring an attractive climate for pharmaceutical research.
- The Government's Science and Technology (S&T) Strategy announced in May 2007 which encourages a more competitive Canadian economy and improved quality of life for Canadians through science and technology. Merck Frosst seeking to ensure S&T Strategy encourages a more competitive environment for biopharmaceutical innovation in Canada.
- The National Pharmaceutical Strategy as agreed to by First Ministers in 2004, with a focus on options for catastrophic pharmaceutical coverage. Merck Frosst Canada seeking to ensure that Canadians' ability to access the medicines they need is increased.
Regulation
- Health Canada Health Products and Foods Branch Cost Recovery Proposal for Human Drug User Fees. Merck Frosst Canada seeking to ensure that renewed user fees adequately fund a safe and efficient review process.
- Patented Medicine Prices Review Board (PMPRB) Regulations identifying information to be reported to the PMPRB. Merck Frosst Canada seeking to ensure that the information being collected is consistent with PMPRB's mandate to prevent excessive pricing while ensuring an attractive climate for pharmaceutical research.
- Patented Medicines (Notice of Compliance) Regulations which seek to balance patent rights and cost savings. Merck Frosst Canada seeking to ensure that patent rights are respected and are internationally competitive.
Communication Techniques
-
Written communication
-
Oral communication
-
Grass-roots communication
Government Institutions
-
Canadian International Development Agency (CIDA)
-
Canadian International Trade Tribunal (CITT)
-
Federal Office of Regional Development – Quebec (FORD[Q])
-
Finance Canada (FIN)
-
Foreign Affairs and International Trade Canada (DFAITC)
-
Health Canada (HC)
-
Industry Canada
-
Justice Canada (JC)
-
Members of the House of Commons
-
National Research Council (NRC)
-
Patented Medicine Prices Review Board (PMPRB)
-
Prime Minister's Office (PMO)
-
Privy Council Office (PCO)
-
Procurement Review Board of Canada (PRB)
-
Public Health Agency of Canada (PHAC)
-
Public Safety and Emergency Preparedness Canada (PSEPC)
-
Senate of Canada
-
Solicitor General Canada (SGC)
-
Treasury Board Of Canada Secretariat (TBS)
In-house Corporation Details
Description of activities
At Merck Frosst, patients come first. Merck Frosst Canada Ltd. is a research-driven pharmaceutical company. Merck Frosst discovers, develops and markets a broad range of innovative medicines to improve human health. The Merck Frosst Centre for Therapeutic Research, one of the largest biomedical research facilities in Canada, has the mandate to discover new therapies for the treatment of respiratory diseases, inflammatory diseases, diabetes, osteoporosis and hypertension. Merck Frosst is one of the top 20 R&D investors in Canada, with an investment of $114 million in 2006. The Company is committed to fostering partnerships to deliver the most valuable health outcomes for Canadian patients. Merck Frosst is a recognized leader in the treatment of asthma, osteoporosis, HIV/AIDS, glaucoma, prostate disease, migraines and infectious diseases. The Company also markets an extensive line of cardiovascular products for high blood pressure, elevated cholesterol and heart failure as well as a broad range of vaccines. Based in Montréal, Quebec, Merck Frosst employs nearly 1,600 people including more than 300 of the world's leading scientific personnel. It is also firmly committed to science education and sponsors a number of programs designed to spark young people's interest in science. More information about Merck Frosst is available at http://www.merckfrosst.com
Responsible officer name and position during the period of this registration
DAWN GRAHAM,
PRESIDENT
Government funding
No government funding was received during the last completed financial year.
In-house Corporation Contact Information
Address:
16711 TransCanada Highway
Kirkland, QC H9H 3L1
Canada
Telephone number:
514-428-2609
Parent Company Information
- MERCK FROSST COMPANY
-
1959 Upper Water Street
Suite 900
Halifax, NS B3J 2X2
Canada
Subsidiary Beneficiary Information
MERCK FROSST CANADA LTD. does not have any subsidiaries that could have a direct interest in the outcome of the undertaking
Lobbyists Details
Senior Officers whose lobbying activities represent less than 20% of their Duties
- Michel Cimon,
Executive Director, Medical Research |
No public offices held
- Richard Garant,
Executive Director, Business Unit 4 |
No public offices held
- Dawn Graham,
President |
No public offices held
- Bernard Houde,
Vice President, Legal and Communications |
No public offices held
- Michael Luther,
Vice President & Site Head, Basic Research, MRL |
No public offices held
- Gregg Szabo,
Executive Director, Policy and Reimbursement |
No public offices held
Senior Officers and Employees whose lobbying activities represent 20% or more of their Duties
- Kathy Armstrong,
Manager, Policy - Health - Ontario |
No public offices held
- Christian Blouin,
Director, Public Health |
No public offices held
- Mark Gibson,
Manager, Policy Planning |
No public offices held
- Louis Lamarche,
National Manager - Public Health |
No public offices held
- Robert Livingston,
Director, Federal Government Affairs |
No public offices held
- Jean-Pierre Metabanzoulou,
Senior Manager, Compliance and Audits |
No public offices held
- Sandra Wainwright,
Director - Regulatory Affairs |
No public offices held
